Kenneth Chinsky, MD
Pulmonary Disease · Woodstock, GANPI 1508833112
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $30,468 of the $34,550 with a category attached, or 88.2%. 22 manufacturers reported payments, led by Verona Pharma, Inc. at 40.4% of the total. 2025 is the largest year on record at $22,892, 2.7 times the $8,373 reported in 2019. Among pulmonary disease clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 104 payments — averaging $332.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Verona Pharma, Inc.$14K
- Boehringer Ingelheim$10K
- GSK$9K
- Pfizer$820
- Bayer$325
- Gilead$146
- plus $686 from 16 others
Across 80 payments — averaging $3991.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$282K
- AstraZeneca$33K
- Mylan Specialty L.p.$4K
What the payments were for
- Consulting fees$1,1253%
- Speaking & faculty fees$30,46888%
- Travel & lodging$8833%
- Food & beverage$2,0456%
- Education$120%
- Gifts$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Verona Pharma, Inc. | 14 | $13,958 |
| Boehringer Ingelheim | 22 | $10,095 |
| GSK | 25 | $8,521 |
| Pfizer | 2 | $820 |
| Bayer | 2 | $325 |
| Gilead | 7 | $146 |
| Jazz Pharmaceuticals Inc. | 2 | $124 |
| AstraZeneca | 7 | $120 |
| Regeneron Healthcare Solutions, Inc. | 6 | $119 |
| Pulmonx Corporation | 1 | $63 |
| Johnson & Johnson(2 entities) | 3 | $53 |
| Harmony Biosciences LLC | 2 | $38 |
| Insmed, Inc. | 2 | $27 |
| Idorsia Pharmaceuticals US Inc | 1 | $21 |
| Azurity Pharmaceuticals, Inc. | 1 | $19 |
| Viatris Specialty LLC | 1 | $18 |
| Grifols USA, LLC | 1 | $16 |
| Advanced Respiratory, Inc | 1 | $15 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $15 |
| Mylan Specialty L.p. | 1 | $13 |
| Circassia Inc. | 1 | $13 |
| Actelion Pharmaceuticals US, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$34,550 in reported general payments places this provider in the 90th percentile of 365 pulmonary disease providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 850 | $663,135 |
| OfevNintedanib Esylate | 18 | $232,998 |
| Fasenra PenBenralizumab | 15 | $93,266 |
| Dupixent PenDupilumab | 22 | $85,159 |
| Breo ElliptaFluticasone/Vilanterol | 138 | $64,894 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 121 | $62,338 |
| TezspireTezepelumab-Ekko | 12 | $53,702 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 72 | $52,225 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 71 | $40,755 |
| Spiriva RespimatTiotropium Bromide | 36 | $24,264 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 89 | $16,411 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 441 | $14,653 |
| Bevespi AerosphereGlycopyrrolate/Formoterol Fum | 23 | $10,017 |
| Tiotropium Bromide | 12 | $9,144 |
| SymbicortBudesonide/Formoterol Fumarate | 32 | $8,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta | $8,521 | $774,8871,082 claims |
| Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat | $10,095 | $327,764192 claims |
| AstraZenecaTezspire, Breztri Aerosphere, Bevespi Aerosphere, Symbicort | $120 | $124,733139 claims |
| PfizerEliquis | $820 | $8,16314 claims |
| Johnson & JohnsonXarelto | $53 | $6,93911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 365 pulmonary disease providers in Georgia.
Other pulmonary disease in Woodstock
- Lawrence McDermottSavannah$963K
- Vivek SambharaGainesville$417K
- Chad MillerAustell$382K
- Nehal BhattAthens$371K
- Maria MascoloRincon$358K
- Colin SwensonAtlanta$255K
- David MillerDecatur$206K
- Michael MullinsSavannah$132K
- Hitendra PatelMarietta$104K
- Eric FlenaughAtlanta$93K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.